Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the promotion of Sarah Jorgensen to senior brand manager for the company’s U.S. Swine Business. Jorgensen, who joined BIVI in February 2007, was a swine sales representative servicing key accounts.
In her new role, Jorgensen is responsible for the development and implementation of brand strategies and marketing initiatives to support the company’s FLEX line of swine vaccines. Before joining BIVI, Jorgensen spent five years in animal health product sales positions, including four years with Pfizer Animal Health as territory manager for its swine and equine business units. She has a bachelor of science degree in animal science from the University of Illinois at Urbana-Champaign.
Lara Sheeley, senior associate director, BIVI Swine Business, says Jorgensen’s swine product knowledge and experience helping swine producers better manage disease challenges in their systems will be invaluable in her new marketing role. “Sarah has a proven track record of working with veterinarians, swine producers and industry leaders to develop and implement a wide range of effective disease control solutions,” Sheeley says. “We are excited to put that expertise to good use as we continue to market our FLEX product line and services.”
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com